5PSQ-109 Role of the pharmacist in the approach to vaccination of immunocompromised patients treated with biologic drugs
Year: 2025
Type: conference-paper
Study design: Observational Study
Abstract: Background and Importance Patients diagnosed with IBD are more susceptible to infections and potentially serious complications, because of the underlying disease and the immunosuppressive treatment (corticosteroids, immunosuppressants or biologic drugs). It is therefore recommended that people with IBD ensure that their vaccination schedule is up to date, particularly pneumococcal and influenza vaccination. Aim and Objectives The objective was to analyse the vaccination of paediatric patients diagnosed with inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn’s disease (CD), who are being treated with biological drugs. Material and Methods An observational, retrospective, cross-sectional study was conducted in a tertiary care hospital. Patients under 18 years of age with a confirmed diagnosis of IBD, on active treatment with biologic drugs for at least six months and without contraindications for vaccination were included. Data were obtained by reviewing the electronic medical records. The following information was collected: demographic data, type of IBD, biological agent and the vaccination status of the patients in accordance with the guidelines established by the Andalusian Health Service, and specifically adherence to annual influenza vaccination (Instruction DGSPyOF-6/2023) and pneumococcal vaccination in risk groups (Instruction DGSPyOF-10/2023). Results Thirty-three paediatric patients were included, 56% were female. Mean age was 14 years. 78.8% were diagnosed with CD and 21.2% with UC. Among patients with CD, 30.75% received infliximab, 50% adalimumab, 15.4% ustekinumab and 3.85% infliximab plus vedolizumab Among those with UC, 85.7% were treated with adalimumab and 14.3% with infliximab.All of them were adequately vaccinated against hepatitis B, measles, rubella and mumps (MMR vaccine) and tetanus, diphtheria and pertussis (Tdap vaccine). The percentage of unvaccinated patients was as follows: 51.51% for influenza vaccine, 24.4% for pneumococcal vaccine, 20% for hepatitis A, 17% for human papillomavirus (HPV), 14% for COVID-19 and 2% for inactivated poliovirus. Conclusion and Relevance The results indicate that it is necessary to improve adherence to vaccination schedules, especially for influenza, pneumococcal infections and COVID-19 vaccines, which are vital to reduce the risks and complications of infection in immunocompromised patients. References and/or Acknowledgements Conflict of Interest No conflict of interest
Authors: F Perez-Periañez, L Rodriguez-de Francisco, M Ladron-Deguevara, A Lopez-Gomez, M López Feijoo, S Flores-Moreno
Institution: Hospital Universitario Virgen del Rocío
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4408376385